Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant

Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01449-9 · Cited by 425

Persistence of SARS-CoV-2 Antibodies for a Year Following SARS-CoV-2 Vaccinations (BBV152 and ChAdOx1 nCoV-19)

Dwivedi, T., Raj, A., Das, N., Gupta, R., Bhatnagar, S., Mohan, A., & Guleria, R. (2023) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01149-w · Cited by 2

Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation

Afridonova, Z. E., Топтыгина, А. П., & Semikina, E. L. (2024) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-sim-17596 · Cited by 2

The continuance intention to vaccinate against COVID-19: An empirical study from Malaysia

Hwang, L.-A., Vaithilingam, S., Ng, J. W. J., Nair, M. S., Ahmed, P. K., & Musa, K. I. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301383 · Cited by 2

COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2

West, G. E., Morse, R. B., Sievers, B. L., Abdullahi, A., Kamelian, K., Cheng, M. T. K., Bradley, J. R., Baker, S., Graves, B., Stark, H., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01469-x · Cited by 2

A Retrospective Population Study of 385 191 Positive Real-Time Reverse Transcription–Polymerase Chain Reaction Tests For SARS-CoV-2 from a Single Laboratory in Katowice, Poland from April 2020 to July 2022

Morawiec, E., Bednarska‐Czerwińska, A., Pudełko, A., Strychalska, A., Broncel, M., Sagan, D., Madej, A., Jasińska-Balwierz, A., Staszkiewicz, R., Sobański, D., et al. (2022) · Medical Science Monitor · doi:10.12659/msm.938872 · Cited by 2

Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients—Authors´ Reply

Stumpf, J., & Hugo, C. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100244 · Cited by 2

Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19

Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Challener, D. W., Breeher, L. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac058 · Cited by 2

Immune responses to SARS-CoV-2 infection and COVID-19 vaccines

Sharma, B. R., & Veeranna, R. P. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00074 · Cited by 3

Adjusted COVID-19 booster schedules balance age-dependent differences in antibody titers benefitting risk populations

Müller, L., Andrée, M., Moskorz, W., Drexler, I., Hauka, S., Ptok, J., Walotka, L., Grothmann, R., Hillebrandt, J., Ritchie, A., et al. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1027885 · Cited by 2

COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)

Seegers, V., Rousseau, G., Zhou, K., Blanc-Lapierre, A., Bigot, F., Mahammedi, H., Lambert, A., Moreau-Bachelard, C., Campone, M., Conroy, T., et al. (2022) · Cancers · doi:10.3390/cancers14225547 · Cited by 2

Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs

Meca‐Lallana, V., Esparcia-Pinedo, L., Aguirre, C., Díaz-Pérez, C., Gutiérrez-Cobos, A., Sobrado, M., Carabajal, E., del Río, B., Ropero, N., Villagrasa, J. R., et al. (2023) · Clinical Immunology Communications · doi:10.1016/j.clicom.2023.02.001 · Cited by 2

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients

Prayongrat, A., Noppaving, P., Chobarporn, T., Sudhinaraset, N., Teeyapun, N., Pakvisal, N., Jantarabenjakul, W., Sophonphan, J., Lertbutsayanukul, C., & Poovorawan, Y. (2023) · Vaccines · doi:10.3390/vaccines11071135 · Cited by 2

Mandatory Vaccination against COVID-19: Qualitative Analysis of Responses to Open-Ended Questions

Giannakou, K., Soulioti, E., & Kyprianidou, M. (2023) · Hygiene · doi:10.3390/hygiene3030021 · Cited by 2

Evaluation of Anti-SARS-CoV-2 IgG antibody response following COVISHEILD vaccination: A comparison between previously infected and non-infected cohorts

Ahmed, S., Zakir, H. M., Mamunur, R. M., Istiak, A., Zahirul, I. M., Meherab, H., & Hasan, R. (2023) · Journal of Vaccines and Immunology · doi:10.17352/jvi.000058 · Cited by 1

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment

Wanchaijiraboon, P., Teeyapun, N., Pakvisal, N., Sainamthip, P., Susiriwatananont, T., Zungsontiporn, N., Suntronwong, N., Vichaiwattana, P., Klinsawat, W., Wanlapakorn, N., et al. (2022) · Vaccines · doi:10.3390/vaccines10101662 · Cited by 2

Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 VaccinesPreprint

Wang, F.-Z., Huang, B., Lv, H., Feng, L., Ren, W., Wang, X., Tang, L., Liu, Q., Wu, D., Zheng, H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065610 · Cited by 2

Persistent Maintenance of Atypical Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall ResponsePreprint

Pušnik, J., König, J., Mai, K., Richter, E., Zorn, J., Proksch, H., Schulte, B., Alter, G., & Streeck, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4072040 · Cited by 2

Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina

Eliçabe, R. J., Distel, M. N., Jofre, B. L., Leporati, M., Silva, J. E., Arias, J. L., Gorlino, C. V., Funes, S. C., Velazquez, M., Vitale, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.11.019 · Cited by 1

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies

Aiello, A., Navarra, A., Haggiag, S., Ruggieri, S., Cuzzi, G., Vanini, V., Salmi, A., Notari, S., Altera, A. M. G., Meschi, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1682049 · Cited by 1

Hybrid immunity following SARS-CoV-2 infection and vaccination is associated with more sustained antibody levels, and lower reinfection risk

Che-Kamaruddin, N., Johari, J., Yahaya, H., Zainal, N., Nguyen, H., Hontz, R. D., Letizia, A. G., & AbuBakar, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-55396-x · Cited by 1

Antibody response to receptor-binding domain of SARS-CoV-2 spike protein following vaccination and natural infection with SARS-CoV-2

Rahman, F., Mazumder, S., Farook, S., Deb, P., Saha, S. P., Akter, F., Jilani, M. S. A., & Haq, J. A. (2022) · IMC Journal of Medical Science · doi:10.55010/imcjms.17.009 · Cited by 1

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Gisondi, P., Simón, D., Alarcón, I., Pournara, E., & Puig, L. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2167487 · Cited by 1

Myocarditis following vaccination with Pfizer-BioNTech BNT162b2 against coronavirus infection (COVID-19)

Mevorach, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00019-0 · Cited by 1

Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology

Song, Z., Luo, Q., Wan, L., Zhu, Q. K., Liu, R., Yin, X., Lu, X., Wei, L., Xiang, Z., & Zou, Y. (2023) · Vaccines · doi:10.3390/vaccines11020442 · Cited by 1

Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh

Hossain, M. I., Sarker, P., Raqib, R., Rahman, M. Z., Hasan, R., Svezia, C., Rahman, M., & Amin, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128330 · Cited by 1

Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study

Meher, T., Pradhan, S. K., Hatei, S. P., Majhi, S. C., Panda, A., Mund, S. R., & Mishra, S. K. (2023) · Cureus · doi:10.7759/cureus.46370 · Cited by 1

Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities

Suita, A., Ohfuji, S., Kasamatsu, A., Kondo, K., Nakata, H., Kita, T., Deguchi, A., Fujimoto, M., Iba, K., Sakamoto, H., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100412 · Cited by 1

Dose Intervals and Time since Final Dose on Changes in Metabolic Indices after COVID-19 Vaccination

Alghamdi, A. A., Wani, K., Alnaami, A. M., & Al‐Daghri, N. M. (2023) · Vaccines · doi:10.3390/vaccines11121746 · Cited by 1

Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls

Németh, D., Vágó, H., Tóthfalusi, L., Ulakcsai, Z., Becker, D. A., Szabo, Z., Rojkovich, B., Gunkl-Tóth, L., Merkely, B. P., & Nagy, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397052 · Cited by 1

Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose

Kim, H. H., Lee, H., Hennighausen, L. G., Furth, P. A., Sung, H., & Huh, J. W. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100565 · Cited by 1

Longitudinal Immunological Analysis of Portuguese Healthcare Workers Across the COVID-19 Pandemic Reveals Differences in the Humoral Immune Response to Vaccines

Vilela, L., Silva, A. G., Cruz, A. S., Sousa, M., Costa, M., Fonseca, F., Campino, S. G., Clark, T. G., & Miranda, A. (2024) · Vaccines · doi:10.3390/vaccines12121358 · Cited by 1

Comparison of hospitalizations and deaths from COVID-19 2021 versus 2020 in Italy: surprises and implications

Donzelli, A., Alessandria, M., & Orlando, L. (2021) · F1000Research · doi:10.12688/f1000research.73132.1 · Cited by 1

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Iketani, S., Liu, L., Nair, M. S., Chandrashekar, A., Mohri, H., Wang, M., Barouch, D. H., Huang, Y., & Ho, D. D. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2006581 · Cited by 1

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis

Liebers, N., Schönland, S. O., Speer, C., Edelmann, D., Schnitzler, P., Kräusslich, H., Müller‐Tidow, C., Hegenbart, U., & Dietrich, S. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000688 · Cited by 1

Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis

Hernández-Porto, M., García, S., Delgado, T., Rodriguez, Y., Aguirre‐Jaime, A., Campos, S., Hernández-Sánchez, C., Lorenzo, C., & Lecuona, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.05.065 · Cited by 1

Pros and Cons for COVID-19 Vaccination and Boost of Young Adults in Light of Recent Literature

Nemunaitis, J. J., Lehmann, P., & Willey, J. C. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.2943 · Cited by 1

The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study

Widysanto, A., Prasetya, I. B., Meriyanti, T., Sungono, V., Setiawan, D. L., Gunawan, E., Adiputra, B., Lorens, J. O., Santi, T., Pradhana, C. M. L., et al. (2022) · Infectious Medicine · doi:10.1016/j.imj.2022.10.001 · Cited by 1

Changing Patterns of SARS-CoV-2 Seroprevalence: A Snapshot among the General Population in Kuwait

Alfouzan, W. A., Altawalah, H., Al-Sarraf, A. J., Alali, W. Q., Al-Fadalah, T., Al-Ghimlas, F., Alajmi, S., Alajmi, M., AlRoomi, E., Jeragh, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020336 · Cited by 1

Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur–uracil as postoperative adjuvant chemotherapy

Nishikubo, M., Tanaka, Y., Mitsui, S., Doi, T., Hokka, D., Hojo, W., Sakai, H., Funakoshi, Y., Yakushijin, K., Ohji, G., et al. (2023) · Surgery Today · doi:10.1007/s00595-023-02649-1 · Cited by 1

KNOWLEDGE, ATTITUDE AND AWARENESS OF MEDICAL AND PARAMEDICAL STUDENTS TOWARDS COVID-19 BOOSTER VACCINATION IN A TERTIARY CARE TEACHING HOSPITAL: A SURVEY BASED CROSS-SECTIONAL STUDY.

Acharya, V., Ramani, Y. R., Mishra, P., Burman, S., & Panigrahy, S. (2023) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v4i9.628 · Cited by 1

Booster and anergic effects of the Covishield vaccine among healthcare workers in South IndiaPreprint

Kannian, P., Mahanathi, P., Ashwini, V., & Kumarasamy, N. (2021) · medRxiv · doi:10.1101/2021.08.04.21261601 · Cited by 1

Modeling The Impact of Vaccination On COVID-19 And Its Delta VariantPreprint

Wang, J., Chan, Y.-C., Niu, R., Wong, E. W. M., & van Wyk, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-1171015/v1 · Cited by 1

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infectionPreprint

Seow, J., Shalim, Z. A., Graham, C., Kimuda, S., Pillai, A., Lechmere, T., Kurshan, A., Khimji, A. M., Snell, L., Nebbia, G., et al. (2023) · bioRxiv · doi:10.1101/2023.03.30.534872 · Cited by 1

The nonspecific effects of COVID-19 vaccination upon non-COVID-19 all-cause mortality (NCACM) in the population of England: Effects of age, sex, COVID-19 variant, vaccination history, and time in a real-world study from Jan-21 to May-23Preprint

Jones, R., & Ponomarenko, A. (2024) · Preprints.org · doi:10.20944/preprints202401.0333.v1

Vaccine against SARS-CoV-2 in previously infected health care workers

Parisi, S. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103556

COVID vaccination: What's next?

Heffernan, C. (2021) · Practice Nursing · doi:10.12968/pnur.2021.32.10.420

Status of Humoral and Cellular Immune Responses within 12 Months Following CoronaVac Vaccination Against COVID-19Preprint

Zhao, W., Chen, W., Li, J., Cheng, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3945456

Assessing the Potential Impact of Immunity Waning on the Dynamics of COVID-19: An Endemic Model of COVID-19Preprint

Rabiu, M., & Iyaniwura, S. A. (2021) · Research Square · doi:10.21203/rs.3.rs-1109572/v1

Comparative analysis of antibody production by mRNA 1273, AZD 1222 and BBIBP-CorV on elderly people suffering from different co-morbidity in BangladeshPreprint

Hoque, A. M., Rahman, M. M., Parvez, S., Imam, H., Nahar, N., & Chowdhury, F. U. H. (2021) · medRxiv · doi:10.1101/2021.11.15.21266338

Le variant delta du SRAS-CoV-2 : revue de la littérature

Baziz, A., Chaib, R., Aberkane, S., Bougofa, M., Djebabra, M., & Mennai, I. (2022) · Batna Journal of Medical Sciences (BJMS) · doi:10.48087/bjmsra.2022.s913

Reply

Zhang, L., Chan, F. K. L., & Ng, S. C. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.02.022

Comparison of vaccine efficacy must be based on good clinical data–Authors’ reply

Taib, N. A. A., Raja, D. B., Teo, A. K. J., Kamarulzaman, A., William, T., Arvinder-Singh, H. S., Mokhtar, S. A., Ting, C., Yap, W. A., Chan, M. Y. K., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100413

Strategy construction to minimize the limitation of respiratory viral vaccine development

Roy, R. P., & Devi, L. (2022) · Indian Journal of Microbiology Research · doi:10.18231/j.ijmr.2022.001

Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE StudyPreprint

Khan, Q. J., Bivona, C. R., Martin, G. A., Zhang, J., Liu, B., He, J., Li, K. H., Nelson, M., Williamson, S. K., Doolittle, G. C., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3936503

Assessment of the humoral immunity induced by Sputnik V Covid-19 vaccine (GAM-COVID-VAC) in healthcare workers

Córdova, E., Lespada, M. I., Cecchini, D. M., Nieto, F., Palonsky, S., Badran, M., Bernasconi, S. V., Bacelar, B., Morganti, L., Garibaldi, F., et al. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacune.2022.05.003

Effectiveness of COVID-19 Vaccination In Healthcare Workers in Shiga Prefecture, JapanPreprint

Chano, T., Yamashita, T., Fujimura, H., Kita, H., Ikemoto, T., Kume, S., Morita, S., Suzuki, T., & Kakuno, F. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4149842

Covid-19 Vaccination Responses In A Cohort Of Patients With Immunodeficiency- Clinical Experience From One Centre

Dziadzio, M. (2021) · Journal of Immunology and Allergy · doi:10.37191/mapsci-2582-6549-2(2)-024

Waning of humoral immunity and affecting factors after BNT162b2 vaccination: a cohort study with latent growth curve model in FukushimaPreprint

Kobashi, Y., Takebayashi, Y., Yoshida, M., Kawamura, T., Shimazu, Y., Kaneko, Y., Nishikawa, Y., Nakayama, A., Takita, M., Zhao, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1909404/v1

Mucosal immunity and antibody anergy in COVID-exposed Covishield vaccineesPreprint

Kannian, P., Mahanathi, P., Gracemary, A., Kumarasamy, N., & Challacombe, S. (2022) · medRxiv · doi:10.1101/2022.09.06.22279625

KINETICS OF SARS-CoV-2 NEUTRALIZNG ANTIBODIES AFTER TWO DOSES OF BNT162b2, (BioNTech/Pfizer) Vaccine

Trajkovska, K. T., Emin, M., Ampova, H., Petrushevska-Stanojevska, E., Kostovska, I., Bogdanska, J., Brezovska, J., & Topuzovska, S. (2021) · Journal of Morphological Sciences · doi:10.55302/jms2143198tt

Serosurvey of SARS-COV-2 at a large public universityPreprint

Hou, C., Williams, S., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · medRxiv · doi:10.1101/2023.02.05.23285494

A community-based study on willingness and predictors to receive precautionary dose of COVID-19 vaccine in Puducherry

Dakshinamurthy, S., Chellamuthu, L., & Rajendran, G. (2023) · International Journal of Academic Medicine · doi:10.4103/ijam.ijam_79_22

Evaluation of the Diagnostic Performance of Two Automated SARS-CoV-2 Neutralization Immunoassays following Two Doses of mRNA, Adenoviral Vector, and Inactivated Whole-Virus Vaccinations in COVID-19 Naïve Subjects

Csoma, E., Koroknai, Á. N., Sütő, R., Szilágyi, E. S., Pócsi, M., Nagy, A. C., Bíró, K., Kappelmayer, J., & Nagy, B. (2023) · Microorganisms · doi:10.3390/microorganisms11051187

Six months follow up of hemodialysis patients after SARS-CoV-2 vaccinations: Effects of the booster dose and vaccine t

Murt, A., Altıparmak, M. R., Dinç, H. Ö., Yalın, S. F., Meşe, M., Yadigar, S., Yıldız, Z., Kocazeybek, B. S., Pekpak, M., & Ataman, R. (2023) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1313206

Immunoglobulin G follow-up and immune response longevity analysis in SARS-CoV-2 convalescent patients and vaccinated individuals: A longitudinal analysis

Maki, F. M., AL-Thwani, A. N., Jiad, K. S., & Musafer, K. N. J. (2023) · Human Antibodies · doi:10.3233/hab-230004

Efficacy of COVID-19 Vaccines against Mortality among COVID-19 Cases of Indore, Central India

Bansal, D., Avashia, S., Bhargava, S., & Jha, K. (2023) · Indian Journal of Respiratory Care · doi:10.5005/jp-journals-11010-1017

Immunological response in health care workers post COVID-19 vaccination

Sidhu, S. K., Singh, K., Kaur, S., Jairath, M., & Kaur, A. (2023) · Annals of Geriatric Education and Medical Sciences · doi:10.18231/j.agems.2023.006

Can long-term COVID-19 vaccination be improved by serological surveillance?: a modeling study for MozambiquePreprint

Liu, C. Y., Shioda, K., Kraay, A. N. M., Massora, S., de Jesus, Á., Massinga, A. J., Monjane, C., Omer, S. B., Jenness, S. M., Nelson, K., et al. (2023) · medRxiv · doi:10.1101/2023.08.29.23294793

Is high COVID-19 vaccination reducing natural immunity?Preprint

Roy, I., & Chapungu, L. (2023) · doi:10.22541/au.165151767.73338695/v2

Evaluation of the Effects of Coronavirus Vaccination Status on Inpatient Demographics and Clinical and Laboratory Data

Girgin, A., Ileri, F., Kaya, S., & Koca, N. (2023) · Cureus · doi:10.7759/cureus.47794

Modeling and analyzing COVID-19 infections in South Africa

Song, T., Wang, Y., Wang, C., & An, Q. (2023) · International Journal of Biomathematics · doi:10.1142/s1793524523501036

Is high COVID-19 vaccination reducing natural immunity?Preprint

Roy, I., & Chapungu, L. (2023) · doi:10.22541/au.165151767.73338695/v3

IgG responses against SARS-CoV-2 vaccines AZD1222 and BBV-152 and breakthrough infections among health care workers in southern India

Rohit, A., D’Souza, C., Kumar, S., Ct, M., Vinothini, V., Perumal, S., Philip, M., George, R., & Karunasagar, I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25528

SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients

Phornkittikorn, P., Kantachuvesiri, S., Sobhonslidsuk, A., Yingchoncharoen, T., Kiertiburanakul, S., & Bruminhent, J. (2024) · Vaccines · doi:10.3390/vaccines12050541

The Predictors of COVID-19 Immunogenicity Elicited by Vaccines Against SARS-CoV-2 in Stem Cell Transplant Recipients

Elbahr, U. S., Erdem, H., Ankaralı, H. Ç., -, C. E. P. D. L. R., PASTRANA, J., Vineeth, C., HEJRES, S., Kaynar, L., ÖZTÜRK, Ç. P., Abalı, H., et al. (2024) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.202402994

COVID-19 Pandemic: Challenges, Controversies and What we have Learned

Constantinescu, I., Mărunțelu, I., Constantinescu, A.-E., Tălăngescu, A., CONSTANTINESCU, A.-I., & Tizu, M. (2024) · Annals of the Academy of Romanian Scientists Series of Medicine · doi:10.56082/annalsarscimed.2024.1.14

Factors Associated With Severity of COVID-19 Disease in Vaccinated Patients

Bahar, T., Rahman, S., Anne, R. T., Chowdhury, Z. Z., Hossain, M. M., Akter, S., Ali, M., & Wazib, A. (2024) · Journal of Dhaka Medical College · doi:10.3329/jdmc.v31i2.73148

SARS-CoV-2 Antibody Level after Homologous and Heterologous Booster Vaccines: an 18-month Longitudinal Observational Cohort Study in Indonesia

Ardyanto, T. D., Khariri, Agus, T. P., Handayani, S., & Soebandrio, A. (2024) · The Open Public Health Journal · doi:10.2174/0118749445337489240726050131

Symptomatology and IgG Levels before and after SARS-CoV-2 Omicron Breakthrough Infections in Vaccinated Individuals

Paula, N. M., Joucoski, E., Baura, V. A., de Souza, E. M., Pedrosa, F. O., Gonçalves, A. G., & Huergo, L. F. (2024) · Vaccines · doi:10.3390/vaccines12101149

BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy

Płatkowska-Adamska, B., Bociek, A., Kal, M., Zarębska‐Michaluk, D., & Odrobina, D. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09379-0

Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study

Mukenge, E. K., Sumbu, B. M.-M., Nkodila, A. N., Muwonga, J. M., Makulo, J. R. R., Ngole, M. Z., Bepouka, B. I., Longokolo, M. M., Kamwiziku, G. K., Situakibanza, H. N.-T., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10754-4

Teamwork makes the dream work : systemic and mucosal immunity in shaping protection against SARS-CoV-2

Marking, U. W. (2025) · doi:10.69622/28194125.v1

A modular and universal platform for neutralizing-antibody profiling by quantifying antigen-receptor interactions via qPCR

Li, X., Chen, Q., Zhu, Y., Hong, H., Zhou, Z., Wu, Z., & Shi, J. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.115951

Post-reactivation humoral immune response with Soberana 01 vaccine in IPK workers, 2022.

Lisboa, T., Lay, L. D. L. Á. R., Montalvo, C., Viada, C., Álvarez, D., Garcés, M., Gascón, M., Tirado, M. G. G., & Oropesa, S. (2025) · Bionatura journal : · doi:10.70099/bj/2025.02.03.11 · Cited by 1

SARS‐CoV‐2 Antibody Levels and Infections in Multiple Vaccinated Employees Over Time

Sander, I., Kespohl, S., Beine, A., Belting, K., Bünger, J., Weidhaas, S., Hosbach, I., Eisenhawer, C., Gleichenhagen, J., Göcke, P., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70628

Additional file 1 of Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

Kroidl, I., Winter, S., Rubio‐Acero, R., Bakuli, A., Geldmacher, C., Eser, T. M., Deák, F., Horn, S., Zielke, A., Ahmed, M. I. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24077073

Additional file 1 of Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection

Wang, F., Huang, B., Deng, Y., Zhang, S., Liu, X., Wang, L., Liu, Q., Zhao, L., Tang, L., Wang, W., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23621392

HIV patients with poor immune recovery show exhausted CD4+ stem cell memory cells and impaired COVID-19 vaccine response

Scaglioni, S., Lombardi, A., Butta, G. M., Bozzi, G., Centazzo, M., Mariani, B., Muscatello, A., Bono, P., Donnici, L., Conti, M., et al. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110676

Etude phénotypique des variants du SARS-CoV-2 et de leur sensibilité aux anticorps neutralisants et monoclonaux

Boschi, C. (2022) · theses.fr (ABES) · doi:10.70675/2523e81cz0815z4a31za5cczaee28bce546b

Evaluation of Humoral Immunity Induced by Commonly Administered COVID-19 Vaccines in Middle-aged Iranians

Jafari, R., Mohammadi, A., Alirezaie, B., Shahbazi, R., & Emamian, M. H. (2026) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-166803

Performance evaluation of Meso Scale Discovery (MSD) quantitative serological assays for detection of binding (IgG, IgA, IgM) and ACE2 inhibitory antibody levels for SARS-CoV-2

Cincotta, C. M., Coleman, D., Padilla, S., Enoch, J., Lakhal-Naouar, I., Bell, M., Ouellette, J., Mansouri, S., M’Hamdi, O., Darden, J. M., et al. (2026) · Journal of Immunological Methods · doi:10.1016/j.jim.2026.114081

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection among healthcare workers: a prospective cohort study

Mahdavi, S., Enayatrad, M., Goli, S., & Zare, F. (2026) · European journal of medical research · doi:10.1186/s40001-026-04748-4

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01721-6 · Cited by 248

SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 and correlates of protection in the UK general populationPreprint

Wei, J., Pouwels, K. B., Stoesser, N. E., Matthews, P. C., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., et al. (2021) · medRxiv · doi:10.1101/2021.09.13.21263487 · Cited by 11

Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose

Yavlinsky, A., Beale, S., Nguyen, V. G., Shrotri, M., Byrne, T., Geismar, C., Fragaszy, E., Hoskins, S., Fong, W. L. E., Navaratnam, A. M. D., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17914.1 · Cited by 10

Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study

Leong, D. P., Zhang, A., Breznik, J. A., Clare, R., Huynh, A., Mushtaha, M., Rangarajan, S., Stacey, H. D., Kim, P. Y., Loeb, M. B., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281673 · Cited by 10

Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose

Sanna, G., Marongiu, A., Firinu, D., Piras, C., Palmas, V., Galdiero, M., Atzori, L., Caria, P., Campagna, M., Perra, A., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01276-x · Cited by 1